The Department of Justice’s April 2026 final order moved FDA-approved cannabis products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while leaving recreational cannabis in Schedule I. An expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own filing affirming accepted medical use, were submitted in mid-August. As of early September, the presiding administrative law judge continues weighing a recommendation for the DEA Administrator, with parallel D.C. Circuit litigation challenging aspects of the process but a recent appeals court denial of a stay allowing proceedings to advance. These steps, initiated under a December 2025 executive order, shape trader assessments of timelines and scope for any further federal reclassification.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$809,884 Vol.
September 30
2%
December 31
16%
$809,884 Vol.
September 30
2%
December 31
16%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The Department of Justice’s April 2026 final order moved FDA-approved cannabis products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while leaving recreational cannabis in Schedule I. An expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own filing affirming accepted medical use, were submitted in mid-August. As of early September, the presiding administrative law judge continues weighing a recommendation for the DEA Administrator, with parallel D.C. Circuit litigation challenging aspects of the process but a recent appeals court denial of a stay allowing proceedings to advance. These steps, initiated under a December 2025 executive order, shape trader assessments of timelines and scope for any further federal reclassification.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions